Aspects of cancer immunotheraphy

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 79-85

  McKenzie, Ian F C ^a   Apostolopoulos, Vasso ^a   Plebanski, Magdalena ^a   Pietersz, Geoffrey A ^a   Loveland, Bruce E ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen presenting cells; Dendritic cells; H 2Kb; MHC class I; MUC1; Peptide MHC interactions; Tumour immunotherapy; Vaccine

Indexed keywords

BCG VACCINE; CYTOKINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CYTOKINE PRODUCTION; DENDRITIC CELL; GENETIC ENGINEERING; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; SCHISTOSOMIASIS; GENETIC DATABASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; REGULATORY T LYMPHOCYTE;

MYCOBACTERIUM BOVIS BCG;

ANTIGEN PRESENTATION; ANTIGENS; CYTOKINES; DATABASES, GENETIC; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 0037327320     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2002.01140.x     Document Type: Article

References (54)

1. Zhou X, Kao MC, Wong WH. From the Cover: Transitive functional annotation by shortest-path analysis of gene expression data. Proc. Natl Acad. Sci. USA 2002; 99: 12 783-8.
2. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
3. Sotiriou C, Powles TJ, Dowsett M et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4: R3.
4. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-6.
5. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITH1. Database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-9.
6. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
7. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I. A new approach for vaccine design. J. Mol. Biol. 2002; 318: 1293-305.
8. Apostolopoulos V, Pietersz GA, Xing PX et al. The immunogenicity of MUC1 peptides and fusion protein. Cancer Lett. 1995; 90: 21-6.
9. Apostolopoulos V, Xing PX, Trapani JA, McKenzie IF. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br. J. Cancer. 1993; 67: 713-20.
10. Xing PX, Prenzoska J, Quelch K, McKenzie IF. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res. 1992; 52: 2310-17.
11. Xing PX, Reynolds K, Tjandra JJ, Tang XL, McKenzie IF. Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res. 1990; 50: 89-96.
12. Xing PX, Apostolopoulos V, Michaels M, Prenzoska J, Bishop J, McKenzie IF. Phase 1 study of synthetic MUC1 peptides in cancer. Int. J. Oncol. 1995; 6: 1283-9.
13. Karanikas V. Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 1997; 100: 2783-92.
14. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res. 2000; 6: 829-37.
15. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA 1995; 92: 10 128-32.
16. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14: 930-8.
17. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 1997; 159: 5211-18.
18. Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 2000; 48: 588-94.
19. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur. J. Immunol. 1997; 27: 2579-87.
20. Apostolopoulos V, Chelvanayagam G, Xing PX, McKenzie IF. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I, H2 and HLA molecules. J. Immunol. 1998; 161: 767-75.
21. Chelvanayagam G, Apostolopoulos V, McKenzie IF. Milestones in the molecular structure of the major histocompatibility complex. Protein Eng. 1997; 10: 471-4.
22. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a non-canonical high affinity peptide complexed with MHC class I. a novel use of alternative anchors. J. Mol. Biol. 2002; 318: 1307-16.
23. Lees CJ, Apostolopoulos V, Acres B, Ong CS, Popovski V, McKenzie IF. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunol. Immunother. 2000; 48: 644-52.
24. Lees CJ, Apostolopoulos V, McKenzie IF. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization. J. Interferon Cytokine Res. 1999; 19: 1373-9.
25. Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 1997; 15: 1586-93.
26. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen- presentation pathway. Eur. J. Immunol. 2000; 30: 1714-23.
27. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000; 18: 3174-84.
28. Engering AJ, Cella M, Fluitsma D et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 1997; 27: 2417-25.
29. Tan MC, Mommaas AM, Drijfhout JW et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 1997; 27: 2426-35.
30. Stambas J, Pietersz G, McKenzie I, Nagabhushanam V, Cheers C. Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation. Vaccine 2002; 20: 1877-86.
31. Stambas J, Pietersz G, McKenzie I, Cheers C. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine 2002; 20: 1068-78.
32. Apostolopoulos V, Popovski V, McKenzie IF. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J. Immunother. 1998; 21: 109-13.
33. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 2001; 24: 172-83.
34. Apostolopoulos V, Lofthouse SA, Popovski V, Chelvanayagam G, Sandrin MS, McKenzie IF. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat. Biotechnol. 1998; 16: 276-80.
35. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal alpha (1,3) Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med. 1998; 4: 315-20.
36. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res. 2000; 60: 829-33.
37. Salgaller ML, Tjoa BA, Lodge PA et al. Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 1998; 18: 109-19.
38. Thurner B, Haendle I, Roder C et al. Vaccination with mage3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999; 190: 1669-78.
39. Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanomaassociated antigens MART-1 and gp100. J. Immunother. 2000; 23: 487-98.
40. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61: 6451-8.
41. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 2002; 195: 1279-88.
42. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998; 4: 328-32.
43. Chang AE, Redman BG, Whitfield JR et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002; 8: 1021-32.
44. Rieser C, Ramoner R, Holtl L et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int. 1999; 63: 151-9.
45. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 2000; 6: 332-6.
46. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 2001; 50: 337-44.
47. Nair SK, Morse M, Boczkowski D et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 2002; 235: 540-9.
48. Sangro B, Qian C, Schmitz V, Prieto J. Gene therapy of hepato-cellular carcinoma and gastrointestinal tumors. Ann. NY Acad. Sci. 2002; 963: 6-12.
49. Gilbert SC, Schneider J, Plebanski M et al. Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations. Biol. Chem. 1999; 380: 299-303.
50. Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10-and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 1999; 163: 242-9.
51. Stanczuk GA, Sibanda EN, Perrey C et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int. J. Cancer 2001; 94: 792-4.
52. Gray CP, Franco AV, Arosio P, Hersey P. Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int. J. Cancer 2001; 92: 843-50.
53. Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther. 2002; 9: 109-15.
54. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002; 169: 2756-61.